Search Results - "Del Pozo, Vanessa"

Evaluation of VTP‐50469, a menin‐MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium by Kurmasheva, Raushan T., Bandyopadhyay, Abhik, Favours, Edward, Pozo, Vanessa Del, Ghilu, Samson, Phelps, Doris A., McGeehan, Gerard M., Erickson, Stephen W., Smith, Malcolm A., Houghton, Peter J.

“…Background VTP‐50469 is a potent inhibitor of the menin‐MLL1 interaction and is implicated in signaling downstream of EWSR1‐FLI1. Procedure VTP‐50469 was…”
Get full text

Evaluation of entinostat alone and in combination with standard‐of‐care cytotoxic agents against rhabdomyosarcoma xenograft models by Kurmasheva, Raushan T., Bandyopadhyay, Abhik, Favours, Edward, Del Pozo, Vanessa, Ghilu, Samson, Phelps, Doris A., Erickson, Stephen W., Peer, Cody J., Figg, William D., Smith, Malcolm A., Houghton, Peter J.

“…Background Entinostat, a selective class I histone deacetylase inhibitor, has been reported to enhance the activity of cytotoxic agents and suppress expression…”
Get full text

Rapid bacterial detection and antibiotic susceptibility testing in whole blood using one-step, high throughput blood digital PCR by Abram, Timothy J, Cherukury, Hemanth, Ou, Chen-Yin, Vu, Tam, Toledano, Michael, Li, Yiyan, Grunwald, Jonathan T, Toosky, Melody N, Tifrea, Delia F, Slepenkin, Anatoly, Chong, Jonathan, Kong, Lingshun, Del Pozo, Domenica Vanessa, La, Kieu Thai, Labanieh, Louai, Zimak, Jan, Shen, Byron, Huang, Susan S, Gratton, Enrico, Peterson, Ellena M, Zhao, Weian

“…Sepsis due to antimicrobial resistant pathogens is a major health problem worldwide. The inability to rapidly detect and thus treat bacteria with appropriate…”
Get more information

Synergistic Antitumor Activity of Talazoparib and Temozolomide in Malignant Rhabdoid Tumors by Mironova, Elena, Molinas, Sebastian, Pozo, Vanessa Del, Bandyopadhyay, Abhik M, Lai, Zhao, Kurmashev, Dias, Schneider, Eric L, Santi, Daniel V, Chen, Yidong, Kurmasheva, Raushan T

“…Malignant rhabdoid tumors (MRTs) are among the most aggressive and treatment-resistant malignancies affecting infants, originating in the kidney, brain, liver,…”
Get full text

Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models by Bandyopadhyay, Abhik, Favours, Edward, Phelps, Doris A., Pozo, Vanessa Del, Ghilu, Samson, Kurmashev, Dias, Michalek, Joel, Trevino, Aron, Guttridge, Denis, London, Cheryl, Hirotani, Kenji, Zhang, Ling, Kurmasheva, Raushan T., Houghton, Peter J.

“…Background Integrating molecularly targeted agents with cytotoxic drugs used in curative treatment of pediatric cancers is complex. An evaluation was…”
Get full text

Extrasynaptic Communication by De-Miguel, Francisco F, Leon-Pinzon, Carolina, Torres-Platas, Susana G, Del-Pozo, Vanessa, Hernández-Mendoza, Guillermo A, Aguirre-Olivas, Dilia, Méndez, Bruno, Moore, Sharlen, Sánchez-Sugía, Celeste, García-Aguilera, Marco Antonio, Martínez-Valencia, Alejandro, Ramírez-Santiago, Guillermo, Rubí, J Miguel

“…Streams of action potentials or long depolarizations evoke a massive exocytosis of transmitters and peptides from the surface of dendrites, axons and cell…”
Get full text

PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma by Del Pozo, Vanessa, Robles, Andrew J., Fontaine, Shaun D., Liu, Qianqian, Michalek, Joel E., Houghton, Peter J., Kurmasheva, Raushan T.

“…Current therapy is ineffective for relapsed and metastatic Ewing sarcoma (EwS) owing to development of drug resistance. Macromolecular prodrugs potentially…”
Get full text

Abstract LB251: Vertical inhibition of the RAF MEK ERK cascade induces myogenic differentiation, apoptosis and tumor regression in H/NRAS Q61X mutant rhabdomyosarcoma by Garcia, Natalia, Del-Pozo, Vanessa, Yohe, Marielle, Goodwin, Craig, Shackleford, Terry, Wang, Long, Baxi, Kunal, Chen, Yidong, Ignatius, Myron, Wood, Kris, Houghton, Peter, Vaseva, Angelina

“…Abstract Rhabdomyosarcoma (RMS) is the most commonly diagnosed soft tissue sarcoma in children. While the 5-year event-free survival for localized…”
Get full text

Abstract A54: Parallel targeting of RAF/MEK/ERK pathway in RAS-mutant embryonal rhabdomyosarcoma by Vaseva, Angelina V., Bandyopadhyay, Abhik, Pozo, Vanessa Del, Goodwin, Craig M., Gautam, Prson, Wennerberg, Krister, Wood, Kris C., Chen, Yidong, Der, Channing J., Houghton, Peter J.

“…Abstract RAS pathway mutations are found in nearly 75% of high-risk embryonal rhabdomyosarcoma (ERMS). While RAS oncoproteins are well-established therapeutic…”
Get full text

Testing of B7-H3 targeting antibody-drug conjugate (ADC) MGC018 in models of pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC) by Kurmasheva, Raushan, Mosse, Yael P., Del Pozo, Vanessa, Earley, Eric J, Erickson, Stephen W, Groff, David, Kolb, E. Anders, Krytska, Kateryna, Smith, Malcolm A., Tsang, Matthew, Teicher, Beverly A., Gorlick, Richard Greg, Maris, John M., Houghton, Peter

“…Abstract only 10037 Background: B7-H3 (encoded by the CD276 gene) is an immunoregulatory molecule that is widely expressed in pediatric embryonal tumors and…”
Get full text

Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRAS Q61X Mutant Rhabdomyosarcoma by Garcia, Natalia, Del Pozo, Vanessa, Yohe, Marielle E, Goodwin, Craig M, Shackleford, Terry J, Wang, Long, Baxi, Kunal, Chen, Yidong, Rogojina, Anna T, Zimmerman, Sara M, Peer, Cody J, Figg, William D, Ignatius, Myron S, Wood, Kris C, Houghton, Peter J, Vaseva, Angelina V

“…Oncogenic RAS signaling is an attractive target for fusion-negative rhabdomyosarcoma (FN-RMS). Our study validates the role of the ERK MAPK effector pathway in…”
Get full text

Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma by Garcia, Natalia, Del Pozo, Vanessa, Yohe, Marielle E., Goodwin, Craig M., Shackleford, Terry J., Wang, Long, Baxi, Kunal, Chen, Yidong, Rogojina, Anna T., Zimmerman, Sara M., Peer, Cody J., Figg, William D., Ignatius, Myron S., Wood, Kris C., Houghton, Peter J., Vaseva, Angelina V.

“…Abstract Oncogenic RAS signaling is an attractive target for fusion-negative rhabdomyosarcoma (FN-RMS). Our study validates the role of the ERK MAPK effector…”
Get full text

Abstract 1086: PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma by Del Pozo, Vanessa, Robles, Andrew J., Fontaine, Shaun, Liu, Qianqian, Michalek, Joel E., Houghton, Peter J., Kurmasheva, Raushan

“…Abstract Introduction: The Ewing family of sarcomas is the fourth most common highly malignant childhood cancer. Current standard therapy is relatively…”
Get full text

Abstract 1088: An evaluation of patritumab deruxtecan (HER3-DXd, U3-1402) against pediatric PDX models for hepatoblastoma and rhabdomyosarcoma - A report from the NCI PIVOT Program by Kurmasheva, Raushan, Houghton, Peter, Del Pozo, Vanessa, Ghilu, Samson, Nakamura, Ryuichi, Fan, Pang-Dian, Jocoy, Emily, Stearns, Tim, Neuhauser, Steve, Chuang, Jeff, Bult, Carol J., Teicher, Beverly A., Smith, Malcolm A.

“…Abstract Introduction: HER3-DXd is an ADC consisting of a fully human monoclonal antibody to HER3 attached to a topoisomerase I inhibitor payload (DXd, an…”
Get full text